drugset / Trial / NCT00801944

Solifenacin Succinate 5mg or 10mg Once Daily in the Treatment of Urgency Symptoms

NCT00801944

Phase 3 Completed 973 enrolled Astellas Pharma Inc
RandomizedParallel-groupDouble-blindTreatment

Summary

Prospective, double-blind, double-randomised, 2-arm parallel group study. Optimal dose increase. Primary efficacy assessment of OAB symptoms by patient diaries.

Timeline

Start
2004-04
Primary completion
2005-10
Completion
2005-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Solifenacin Small molecule 5 mg Oral
Subject Solifenacin Small molecule 10 mg Oral

Indications